학술논문
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy
Document Type
article
Author
Christopher J. Ferreri; Michelle A. T. Hildebrandt; Hamza Hashmi; Leyla O. Shune; Joseph P. McGuirk; Douglas W. Sborov; Charlotte B. Wagner; M. Hakan Kocoglu; Aaron Rapoport; Shebli Atrash; Peter M. Voorhees; Jack Khouri; Danai Dima; Aimaz Afrough; Gurbakhash Kaur; Larry D. Anderson; Gary Simmons; James A. Davis; Nilesh Kalariya; Lauren C. Peres; Yi Lin; Murali Janakiram; Omar Nadeem; Melissa Alsina; Frederick L. Locke; Surbhi Sidana; Doris K. Hansen; Krina K. Patel; Omar Alexis Castaneda Puglianini
Source
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-9 (2023)
Subject
Language
English
ISSN
2044-5385
Abstract
Abstract Most patients with multiple myeloma experience disease relapse after treatment with a B-cell maturation antigen-targeted therapy (BCMA-TT), and data describing outcomes for patients treated with sequential BCMA-TT are limited. We analyzed clinical outcomes for patients infused with standard-of-care idecabtagene vicleucel, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, at 11 US medical centers. A total of 50 patients with prior BCMA-TT exposure (38 antibody-drug conjugate, 7 bispecific, 5 CAR T) and 153 patients with no prior BCMA-TT were infused with ide-cel, with a median follow-up duration of 4.5 and 6.0 months, respectively. Safety outcomes between cohorts were comparable. The prior BCMA-TT cohort had a lower overall response rate (74% versus 88%; p = 0.021), median duration of response (7.4 versus 9.6 months; p = 0.03), and median progression-free survival (3.2 months versus 9.0 months; p = 0.0002) compared to the cohort without prior BCMA-TT. All five patients who received a prior anti-BCMA CAR T responded to ide-cel, and survival outcomes were best for this subgroup. In conclusion, treatment with ide-cel yielded meaningful clinical responses in real-world patients exposed to a prior BCMA-TT, though response rates and durability were suboptimal compared to those not treated with a prior BCMA-TT.